Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995

Chest

Volumn 115, Issue 3, 1999, Pages 703-707

  Van Andel, Amy E ^a   Reisner, Colin ^a   Menjoge, Shailendra S ^a   Witek, Ted J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Cholinergic antagonists; COPD; Corticosteroids; Drug therapy; Theophylline; adrenergic receptor agonists

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VITAL CAPACITY;

EID: 0033033896     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.3.703     Document Type: Article

References (19)

1. 1 Witek TJ, Schachter EN. Pharmacology and therapeutics in respiratory care. Philadelphia: WB Saunders, 1994; 183-184
2. 2 Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 147:S40-S47
3. 3 Ramsdell J. Use of theophylline in the treatment of COPD. Chest 1995; 107:S206-S209
4. 4 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S121
5. 5 Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8:1398-1420
6. 6 Gross NJ. Airway inflammation in COPD: reality or myth? Chest 1995; 107:S210-S213
7. 7 Barns PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157:S1-S53
8. 8 McEvoy CE Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. Chest 1997; 111:732-743
9. 9 van Schayck CP, Rutten ED. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995; 107:1199-1205
10. 10 Kesten S, Rebuck AS, Chapman KR. Trends in asthma and chronic obstructive pulmonary disease therapy in Canada, 1985 to 1990. J Allergy Clin Immunol 1993; 92:499-506
11. 11 Molfino NA, Nannini LJ Jr, Chapman KR, et al. Trends in pharmacotherapy for chronic airflow limitation in Argentina: 1983-1990. Medicina 1994; 54:103-109
12. 12 Bosco LA, Knapp DE, Gerstman B, et al. Asthma drug therapy trends in the United States, 1972 to 1985. J Allergy Clin Immunol 1985; 80:398-402
13. 13 Jackevicius CD, Joyce P, Kesten S, et al. Prehospitalization inhaled corticosteroid use in patients with COPD and asthma. Chest 1997; 111:296-302
14. 14 Morris JF, Koski A, Temple WP, et al. Fifteen year interval spirometric evaluation of the Oregon predictive equations. Chest 1988; 93:123-127
15. 15 Armitage P. Test for linear trend in proportions and frequencies. Biometrics 1955; 11:375-386
16. 16 Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328:1017-1022
17. 17 Pauwels RA, Lofdahl CG, Pride NB, et al. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOPE): hypothesis and design. Eur Respir J 1992; 5:1254-1261
18. 18 Kesten SK, Chapman KR. Physician perceptions and management of COPD. Chest 1993; 104:254-258
19. 19 Jatulis DE, Meng Y, Elashoff RM, et al. Preventive pharmacologic therapy among asthmatics: five years after publication of guidelines. Ann Allergy Asthma Immunol 1998; 81:82-88